Clavis Pharma ASA has started recruiting patients for a Phase 3 trial of its lead product for late-stage acute myeloid leukaemia. The clinical update was issued with its first quarter results which showed cash of NOK 333 million on 31 March. ---Subscribe to MedNous to access this article--- Company News
